xiwyxucupewox.blogspot.com
The vaccine probably would be developed atthe company’a Belgium research facility and produced at several influenzaq vaccine manufacturing facilities the company has arouncd the world. GSK (NYSE: GSK) is waitingf for a sample of the H1N1 virus to be delivered from the WorldxHealth Organization. The compangy says it will take about six months from that point for the vaccin tobe developed. Following development, GSK woulf need to receive regulatory approval from Europeannhealth officials. Among the nationsd interested in the vaccine are GreaytBritain (60 million doses), France (50 million Belgium (12.6 million) and Finland (5.3 million). GSK also it in talkss with U.S.
health officials about how it can help withthe nation’s response to H1N1 influenza, Alspach The U.K.-based company, whicuh has 4,000 employees at its North American headquarters in Research Triangle Park, also is in the procesxs of boosting production of its flu treatment Relenza. Companuy official say it will take about 12 weeks to get productionramped up. At that the company intends to produce Relenza at a rate of 50 millionb to 60 million packsa year. Some of that production will occurat GSK’s Zebulon manufacturing which employs about 1,000 people, a number not expected to change due to the Relenza ramp-up.
Earlier this week , a biotechnologty and health technology company basedin Boston, said it developed a vaccine for swine flu that could be produces within seven to 10 once it is approvee by regulators. The synthetic vaccine has not yet been tested in Replikins CEO Samuel Bogoch said the companh is actively seeking a pharmaceutical or academicv partner to conduct clinical trials onthe
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment